Fintel reports that on January 10, 2025, BTIG initiated coverage of ImmunityBio (NasdaqGS:IBRX) with a Buy recommendation.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback